Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667028 | 1.00 | TP53 (0.57) | TP53TSHRPLA2G4BRARBS1PR1 | |
| SCHEMBL8214518 | 0.87 | RARB (0.56) | TP53TSHRPLA2G4BRARBS1PR1 | |
| SCHEMBL8214535 | 0.87 | RARB (0.56) | TP53TSHRPLA2G4BRARBS1PR1 | |
| SCHEMBL8214349 | 0.87 | RARB (0.56) | TP53TSHRPLA2G4BRARBS1PR1 | |
| SCHEMBL27932158 | 0.87 | LSS (0.46) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL27877690 | 0.87 | LSS (0.46) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL12549313 | 0.86 | TP53 (0.51) | TP53TSHRPLA2G4BRARBNR5A1 | |
| SCHEMBL8216185 | 0.85 | RARB (0.54) | TP53TSHRPLA2G4BRARBS1PR1 | |
| SCHEMBL27622343 | 0.83 | PTGER3 (0.44) | — | |
| SCHEMBL9109799 | 0.83 | ALDH1A1 (0.56) | PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | TP53 891/4885TSHR 1612/4885PLA2G4B 1902/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | TP53 892/4885TSHR 1607/4885PLA2G4B 1914/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | TP53 1210/4885TSHR 1383/4885PLA2G4B 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.